Cited by 883Neutrophil, Myeloperoxidase and Oxidative MechanismsVenous Thromboembolism Diagnosis and ManagementPlatelet Disorders and Treatments

Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis

Open access
Demers, Mélanie, Krause, Daniela S., Schatzberg, Daphne, Martinod, Kimberly, Voorhees, Jaymie R., Fuchs, Tobias A., Scadden, David T., Wagner, Denisa D.·2012·Proceedings of the National Academy of Sciences

Abstract

Cancer-associated thrombosis often lacks a clear etiology. However, it is linked to a poor prognosis and represents the second-leading cause of death in cancer patients. Recent studies have shown that chromatin released into blood, through the generation of neutrophil extracellular traps (NETs), is procoagulant and prothrombotic. Using a murine model of chronic myelogenous leukemia, we show that malignant and nonmalignant neutrophils are more prone to NET formation. This increased sensitivity toward NET generation is also observed in mammary and lung carcinoma models, suggesting that cancers, through a systemic effect on the host, can induce an increase in peripheral blood neutrophils, which are predisposed to NET formation. In addition, in the late stages of the breast carcinoma model, NETosis occurs concomitant with the appearance of venous thrombi in the lung. Moreover, simulation of a minor systemic infection in tumor-bearing, but not control, mice results in the release of large quantities of chromatin and a prothrombotic state. The increase in neutrophil count and their priming is mediated by granulocyte colony-stimulating factor (G-CSF), which accumulates in the blood of tumor-bearing mice. The prothrombotic state in cancer can be reproduced by treating mice with G-CSF combined with low-dose LPS and leads to thrombocytopenia and microthrombosis. Taken together, our results identify extracellular chromatin released through NET formation as a cause for cancer-associated thrombosis and unveil a target in the effort to decrease the incidence of thrombosis in cancer patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1200419109

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Demers, M., Krause, D. S., Schatzberg, D., Martinod, K., Voorhees, J. R., Fuchs, T. A., Scadden, D. T., & Wagner, D. D.
Affiliations
  • Boston Children's Hospital (US)
  • Massachusetts General Hospital (US)
Venue
Proceedings of the National Academy of Sciences
Published
2012-07-23
Volume
109
Issue
32
Pages
13076-13081
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2070117107
Cited by
883
References
47
Citations by year
2026: 41 · 2025: 60 · 2024: 83 · 2023: 79 · 2022: 87 · 2021: 101 · 2020: 82 · 2019: 70 · 2018: 55 · 2017: 51 · 2016: 55 · 2015: 49 · 2014: 35 · 2013: 29 · 2012: 6
FWCI
16.78
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • Genentech
  • National Heart, Lung, and Blood Institute (R01HL102101, R01HL044851)
  • National Cancer Institute (K08CA138916)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords
cancer-associated thrombosis, neutrophil extracellular traps, NETosis, procoagulant activity, granulocyte colony-stimulating factor, chronic myeloid leukemia, breast cancer, lung cancer, venous thrombosis, thrombocytopenia, microvascular thrombosis, systemic infection
MeSH terms
Animals, Chromatin, DNA, Enzyme-Linked Immunosorbent Assay, Fluorescence, Histological Techniques, Mice, Inbred BALB C, Neutrophils, Thrombosis, Blotting, Western, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Granulocyte Colony-Stimulating Factor, Statistics, Nonparametric, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review